165 related articles for article (PubMed ID: 23102381)
21. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.
Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879
[TBL] [Abstract][Full Text] [Related]
22. Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population.
Wang H; Liang Z; Li Y; Li B; Liu J; Hong X; Lu X; Wu J; Zhao W; Liu Q; An J; Li L; Pu F; Ming Q; Han Y
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28083915
[TBL] [Abstract][Full Text] [Related]
23. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
[TBL] [Abstract][Full Text] [Related]
24. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials.
Yu J; Mehran R; Clayton T; Gibson CM; Brodie BR; Witzenbichler B; Lincoff AM; Deliargyris EN; Gersh BJ; Pocock SJ; Stone GW; Dangas GD
Catheter Cardiovasc Interv; 2016 Feb; 87(3):391-400. PubMed ID: 26624854
[TBL] [Abstract][Full Text] [Related]
25. Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes.
Stone GW; Mehran R; Steg PG
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):225-227. PubMed ID: 25616930
[No Abstract] [Full Text] [Related]
26. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
Sardi GL; Lindsay J; Waksman R
Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418
[TBL] [Abstract][Full Text] [Related]
27. Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper.
Johnson TW; Marsden D; Mumford A; Pike K; Mundell S; Butler M; Strange JW; Bowles R; Rogers C; Baumbach A; Reeves BC
BMC Cardiovasc Disord; 2014 Apr; 14():44. PubMed ID: 24708700
[TBL] [Abstract][Full Text] [Related]
28. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
Schulz S; Kastrati A; Ferenc M; Massberg S; Birkmeier KA; Laugwitz KL; Kufner S; Gick M; Dommasch M; Schühlen H; Schömig A; Berger PB; Mehilli J; Neumann FJ;
EuroIntervention; 2013 Aug; 9(4):430-6. PubMed ID: 23455033
[TBL] [Abstract][Full Text] [Related]
29. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
[TBL] [Abstract][Full Text] [Related]
30. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
31. Bleeding outcomes after routine transradial primary angioplasty for acute myocardial infarction using eptifibatide and unfractionated heparin: a single-center experience following the HORIZONS-AMI trial.
Moody WE; Chue CD; Ludman PF; Chan YK; Narayan G; Millington JM; Townend JN; Doshi SN
Catheter Cardiovasc Interv; 2013 Sep; 82(3):E138-47. PubMed ID: 23074143
[TBL] [Abstract][Full Text] [Related]
32. Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?
Mahmoud A; Saad M; Elgendy AY; Abuzaid A; Elgendy IY
Cardiovasc Ther; 2015 Aug; 33(4):227-35. PubMed ID: 25879426
[TBL] [Abstract][Full Text] [Related]
33. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.
Navarese EP; Schulze V; Andreotti F; Kowalewski M; Kołodziejczak M; Kandzari DE; Rassaf T; Gorny B; Brockmeyer M; Meyer C; Berti S; Kubica J; Kelm M; Valgimigli M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):201-213. PubMed ID: 25616926
[TBL] [Abstract][Full Text] [Related]
35. Heparin versus bivalirudin for non-primary percutaneous coronary intervention: A post-Hoc analysis of the CPORT-E trial.
Czarny MJ; Hwang CW; Naiman DQ; Lemmon CC; Hasan RK; Wang T; Aversano T
Catheter Cardiovasc Interv; 2017 Sep; 90(3):366-377. PubMed ID: 28160375
[TBL] [Abstract][Full Text] [Related]
36. Bivalirudin started during emergency transport for primary PCI.
Steg PG; van 't Hof A; Hamm CW; Clemmensen P; Lapostolle F; Coste P; Ten Berg J; Van Grunsven P; Eggink GJ; Nibbe L; Zeymer U; Campo dell' Orto M; Nef H; Steinmetz J; Soulat L; Huber K; Deliargyris EN; Bernstein D; Schuette D; Prats J; Clayton T; Pocock S; Hamon M; Goldstein P;
N Engl J Med; 2013 Dec; 369(23):2207-17. PubMed ID: 24171490
[TBL] [Abstract][Full Text] [Related]
37. The bivalirudin paradox: high evidence, low use.
De Servi S; Mariani G; Mariani M; D'Urbano M
J Cardiovasc Med (Hagerstown); 2013 May; 14(5):334-41. PubMed ID: 23442811
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
Jovin IS; Shah RM; Patel DB; Rao SV; Baklanov DV; Moussa I; Kennedy KF; Secemsky EA; Yeh RW; Kontos MC; Vetrovec GW
JACC Cardiovasc Interv; 2017 Jun; 10(11):1102-1111. PubMed ID: 28527778
[TBL] [Abstract][Full Text] [Related]
39. Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Sheikh-Taha M; Ghosn S
J Pharm Pract; 2012 Oct; 25(5):537-40. PubMed ID: 22572222
[TBL] [Abstract][Full Text] [Related]
40. A regional pharmacoinvasive PCI strategy incorporating selected bleeding avoidance strategies.
Chava S; Raza S; El-Haddad MA; Priest J; Ashikaga T; Dauerman HL
Coron Artery Dis; 2015 Jan; 26(1):30-6. PubMed ID: 25279566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
